Nummular Eczema: Coin-Shaped Patches of Irritated Skin

Clinical Overview

Nummular eczema, also known as nummular dermatitis or discoid eczema, is a chronic inflammatory skin condition characterized by distinctive coin-shaped (nummular) lesions typically measuring 1-3 centimeters in diameter. Unlike other eczema variants that present with poorly demarcated erythematous patches, nummular eczema produces well-demarcated, circular lesions that are often hyperpigmented or lichenified. The condition predominantly affects adults, with peak onset in the third to fourth decade of life, though it can occur at any age. Patients frequently report pruritus ranging from mild to severe, which may be worse at night and exacerbated by stress, sweating, and changes in humidity. The lesions may persist for weeks to months and tend to recur in similar locations, suggesting specific areas of predisposition.

Epidemiology

Nummular dermatitis accounts for 15-20% of all eczema cases in dermatology clinics, though population prevalence estimates range from 0.5% to 2.0%. The condition shows a slight male predominance (male-to-female ratio of approximately 1.3:1) and is more common in individuals aged 30-50 years. Occupational exposure to irritants, including healthcare workers and individuals in wet occupations, increases disease risk significantly. Environmental factors play a crucial role—the condition typically worsens during winter months due to reduced humidity and increased reliance on indoor heating systems. Geographic variation exists, with higher prevalence in temperate and cold climates compared to tropical regions. Approximately 40% of patients have a personal or family history of atopic disease (atopic dermatitis, asthma, or allergic rhinitis), suggesting a genetic predisposition component.

Pathophysiology

The pathophysiology of nummular eczema involves multiple interconnected mechanisms. Impaired skin barrier function, as evidenced by elevated transepidermal water loss (TEWL) measurements in lesional and perilesional skin, represents a fundamental defect. Filaggrin mutations, while less frequently implicated than in atopic dermatitis, have been identified in some nummular eczema cases, suggesting genetic contribution to barrier dysfunction. Contact sensitization and irritant responses appear heightened; many patients develop secondary allergic contact dermatitis to topical medications or allergens encountered during treatment. Histologically, lesions demonstrate spongiosis, acanthosis, and often prominent lichenification with hyperkeratosis, particularly in chronic lesions. Inflammatory mediators including interleukin-17 (IL-17), tumor necrosis factor-alpha (TNF-α), and T-helper 2 (Th2) cytokines including IL-4 and IL-13 are elevated in affected skin. The chronic rubbing and scratching perpetuates the itch-scratch cycle, leading to progressive lichenification and potential development of secondary bacterial infections, typically with Staphylococcus aureus colonization observed in 60-80% of lesional sites.

Clinical Presentation

Nummular eczema presents acutely with erythematous papules and vesicles arranged in a circular pattern, which gradually coalesce into well-demarcated coin-shaped plaques measuring 1-3 cm in diameter. Individual lesions progress through distinct stages: initial papulovesicular phase (days 1-3), exudative phase (days 4-7) where lesions may become macerated and oozing, and lichenified phase (weeks 2-8) characterized by dry, thickened, scaly plaques with prominent lichenification. The central portion may sometimes clear, creating an annular appearance. Lesions commonly affect the lower extremities (shins and ankles), dorsal aspects of hands, buttocks, and areas of prior trauma or irritation. Pruritus is often severe and may persist even after apparent resolution of visible lesions. Secondary bacterial infection, manifesting as increased erythema, purulent exudation, and systemic symptoms including fever and malaise, occurs in 30-40% of patients during their disease course. Patients frequently report exacerbations triggered by emotional stress, xerosis (dry skin), exposure to harsh soaps, wool clothing, or environmental irritants. The disease may spontaneously remit but more commonly follows a chronic, relapsing course with periodic flares.

Diagnosis

Diagnosis of nummular eczema is primarily clinical, based on characteristic morphology and distribution of coin-shaped lesions. The key diagnostic criteria include: (1) presence of distinct, circular, well-demarcated lesions typically 1-3 cm in diameter; (2) common location on lower extremities, dorsal hands, and buttocks; (3) variable degree of lichenification and xerosis; (4) absence of vasculitis, secondary syphilis, or other differential diagnoses. Dermoscopy reveals regular reticular pattern with prominent perifollicular changes. Patch testing should be performed if contact sensitization is suspected, particularly given the high incidence of secondary allergen development in these patients. Bacterial culture of purulent drainage is recommended if secondary infection is suspected. Skin biopsy is rarely necessary but demonstrates acanthosis, spongiosis, variable degree of lichenification with hyperkeratosis, and superficial perivascular lymphocytic infiltrate. Elevated IgE levels may be present but are not diagnostic. Evaluation for other causes of circular lesions, including tinea corporis (distinguished by positive KOH preparation or fungal culture and response to antifungal therapy) and cutaneous vasculitis, should be performed. Complete blood count with differential and comprehensive metabolic panel should be obtained before initiating systemic corticosteroids or immunosuppressive therapy.

Treatment Algorithm

Initial management focuses on skin barrier repair and elimination of irritants. Emollients containing ceramides and hyaluronic acid should be applied immediately after bathing while skin is still damp to optimize penetration. Recommended formulations include CeraVe Moisturizing Cream, Eucerin Eczema Relief Cream, or Cetaphil Rich Hydrating Night Cream applied 2-3 times daily. Avoid irritating topical agents including fragrances, dyes, wool, and harsh soaps. Patients should use lukewarm water for bathing and limit shower duration to 5-10 minutes to minimize TEWL.

For mild-to-moderate lesions, topical corticosteroids remain first-line therapy. Medium-potency agents (Class III-IV) are appropriate: triamcinolone acetonide 0.1% cream applied twice daily to affected areas for 2-3 weeks, or betamethasone dipropionate 0.05% lotion twice daily. Higher-potency agents (Class I-II) such as clobetasol propionate 0.05% cream should be reserved for severe, lichenified lesions and limited to short durations (7-10 days) to minimize systemic absorption and skin atrophy risk.

Topical calcineurin inhibitors provide excellent steroid-sparing benefits, particularly for maintenance therapy and prevention of flares. Tacrolimus 0.1% ointment applied twice daily demonstrates efficacy comparable to Class III corticosteroids without cutaneous atrophy risk. Pimecrolimus 1% cream, while less potent, is useful for sensitive facial and intertriginous areas.

For moderate-to-severe or widespread disease inadequately responding to topical therapy, systemic corticosteroids may be necessary. Prednisone 0.5-1.0 mg/kg/day (maximum 60 mg daily) for 2-4 weeks followed by gradual taper (reducing by 5-10 mg weekly) effectively controls acute flares. However, prolonged systemic corticosteroid use is associated with significant adverse effects and should not be used for long-term maintenance.

Systemic immunosuppressive agents are indicated for chronic, severe, or recurrent disease. Dupilumab, a monoclonal antibody targeting IL-4 receptor-alpha, has demonstrated remarkable efficacy in clinical trials. The recommended dose is 600 mg initial loading dose (two 300 mg injections), followed by 300 mg subcutaneous injection every 2 weeks. Improvement is typically evident within 2-4 weeks, with maximal benefit at 16 weeks. Cyclosporine at doses of 2.5-5.0 mg/kg/day divided in two doses remains effective, with response rates of 60-80% in severe nummular eczema. Azathioprine 1.5-2.5 mg/kg/day is a less expensive alternative with slower onset (4-12 weeks) but acceptable efficacy profile. Mycophenolate mofetil (MMF) 1000-1500 mg twice daily shows promise in recent studies with improved tolerability compared to azathioprine.

Secondary bacterial infections require prompt treatment. Culture-guided antibiotic therapy is preferred; empiric treatment with oral cephalexin 500 mg four times daily for 10-14 days or clindamycin 300-450 mg three times daily is appropriate for non-severe infections. For MRSA-positive lesions, trimethoprim-sulfamethoxazole (TMP-SMX) double-strength one tablet twice daily for 10-14 days or doxycycline 100 mg twice daily is recommended. Severe cellulitis may require hospitalization and intravenous therapy (nafcillin 1-2 g IV every 4-6 hours or vancomycin 15-20 mg/kg IV every 8-12 hours).

Pruritus management is critical for treatment success. First-generation antihistamines including hydroxyzine 25-50 mg at bedtime or diphenhydramine 25-50 mg at bedtime may improve sleep quality. Second-generation antihistamines (cetirizine 10 mg daily, loratadine 10 mg daily) provide daytime pruritus control with minimal sedation. Topical agents including menthol 1-2% preparations or pramoxine 1% lotion provide temporary symptomatic relief. Gabapentin 300 mg three times daily (titrating up to 900 mg three times daily) is effective for neuropathic-component pruritus in selected patients.

Prognosis

The natural history of nummular eczema is characterized by a chronic, relapsing-remitting course with variable spontaneous remission rates. Approximately 30% of patients experience spontaneous complete remission within 5 years, while 40% continue with periodic flares managed by topical therapy, and 30% develop chronic, persistent disease. Prognostic factors influencing disease course include: early age of onset (generally associated with better prognosis), limited initial extent (<50% body surface area involvement), absence of secondary bacterial colonization, absence of atopic comorbidities, and good adherence to skin barrier repair measures. Patients with occupational exposure to irritants have longer disease duration and higher relapse rates unless workplace modifications are implemented. Psychological stress, emotional disturbance, and depression negatively impact prognosis through potential alterations in immune function and adherence to therapy. Secondary scarring is uncommon unless significant lichenification or repeated trauma occurs. The potential for development of cutaneous lymphoma is exceedingly rare, estimated at <1% lifetime risk.

When to See a Dermatologist

Initial dermatologic evaluation is recommended for all suspected nummular eczema cases to confirm diagnosis and initiate appropriate therapy. Urgent evaluation is indicated if: (1) lesions show signs of secondary bacterial infection (increasing erythema, purulent drainage, fever); (2) disease is acute and severe, affecting >10% body surface area; (3) patient develops signs of cellulitis or systemic toxicity. Ongoing specialist care is appropriate if: (1) disease fails to respond adequately to topical corticosteroids within 2-3 weeks; (2) patient requires systemic corticosteroid therapy for disease control; (3) systemic immunosuppressive agents are being considered or monitored; (4) significant diagnostic uncertainty exists regarding alternate diagnoses; (5) complications including severe secondary infection, eczema herpeticum, or development of new dermatologic diagnoses occur.

Frequently Asked Questions

Q: Is nummular eczema contagious? A: No, nummular eczema is not contagious. It is a non-infectious inflammatory condition of the skin. You cannot transmit it to others through contact, saliva, or shared personal items. However, if secondary bacterial infection develops, the infected lesions may theoretically transmit bacteria to others, similar to any open wound.

Q: Can stress trigger nummular eczema flares? A: Yes, psychological stress and emotional disturbance are well-documented triggers for nummular eczema exacerbations in approximately 60% of patients. Stress may worsen disease through multiple mechanisms: altered immune regulation favoring Th2 response, increased cutaneous blood flow and transepidermal water loss, and reduced cortical inhibition of itch sensation. Stress management techniques including cognitive behavioral therapy, mindfulness-based stress reduction, and regular physical exercise may improve disease control as adjunctive measures.

Q: How long does nummular eczema typically last? A: Individual lesions typically resolve over 4-8 weeks with appropriate treatment, though timeline varies based on lesion stage at presentation and treatment responsiveness. However, the disease itself follows a chronic course with frequent recurrences. Without specific trigger avoidance and ongoing preventive care, approximately 70% of patients experience one or more significant flares within 12 months. Seasonal variation is common, with winter exacerbations predominating due to decreased environmental humidity.

Q: Which topical corticosteroid is safest for long-term use? A: No topical corticosteroid is truly safe for indefinite long-term use without monitoring. However, lower-potency agents (Class VI-VII) such as hydrocortisone 1% or desonide 0.05% can be used intermittently (2-3 times weekly) for longer periods with reduced atrophy risk. For maintenance therapy, topical calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) are preferred as they do not cause cutaneous atrophy. High-potency agents should be limited to short courses (7-10 days) on severely affected areas, and their use should be periodically reassessed.

References